Coronavirus non-structural protein 6 (NSP6)

Coronavirus non-structural protein 6 (NSP6) is a conserved, multi-pass transmembrane protein that plays a critical role in the replication and pathogenesis of coronaviruses, including SARS-CoV-2 [1, 3]. It primarily localizes to the endoplasmic reticulum (ER), where it works in concert with NSP3 and NSP4 to induce the formation of double-membrane vesicles (DMVs) that serve as protected sites for viral RNA synthesis [1, 4, 13]. NSP6 also acts as a potent immune antagonist by blocking type I interferon (IFN-I) signaling and activating the NLRP3 inflammasome, which contributes to the severe inflammatory response known as a cytokine storm [1, 5, 6]. Furthermore, it manipulates host cellular processes by restricting autophagosome expansion and tethering lipid droplets to DMVs to provide lipids for viral assembly [1, 2, 7]. Because of its essential roles in the viral life cycle and host immune evasion, NSP6 is an attractive target for antiviral drug development [2, 9]. Therapeutic strategies include small molecules like K22 and repurposed drugs such as Haloperidol and PB28 that disrupt NSP6 interactions with host factors like the Sigma-1 receptor (SIGMAR1) [1, 2, 11]. Monitoring mutations in NSP6, such as the ΔSGF deletion, is also vital for understanding viral evolution and potential resistance to therapies [1, 13].

Other names

NSP6Non-structural protein 6nsp6CoV nsp6SARS-CoV-2 nsp6

Inhibition of viral replication organelle formation, restoration of host innate immune signaling (IFN-I), and prevention of NLRP3 inflammasome-mediated inflammation.